{"id":556154,"date":"2021-08-04T19:26:02","date_gmt":"2021-08-04T19:26:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=556154"},"modified":"2021-08-04T19:26:02","modified_gmt":"2021-08-04T19:26:02","slug":"cholestatic-pruritus-market-size-and-share-analysis-clinical-developmental-activities-key-growth-factors-leading-companies-emerging-therapies-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cholestatic-pruritus-market-size-and-share-analysis-clinical-developmental-activities-key-growth-factors-leading-companies-emerging-therapies-and-epidemiology-forecast_556154.html","title":{"rendered":"Cholestatic Pruritus Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Cholestatic Pruritus Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Cholestatic Pruritus Market Size and Share Analysis, Clinical Developmental Activities, Key Growth Factors, Leading Companies, Emerging Therapies, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cholestatic Pruritus Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <strong>Cholestatic Pruritus Market Research Report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Cholestatic Pruritus market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Cholestatic Pruritus treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Cholestatic Pruritus Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/84107fb068311f86c0b18c8b10c04565.jpg\" alt=\"Cholestatic Pruritus Market \" \/>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholestasis is defined as a decrease in bile flow due to the impaired secretion by hepatocytes or due to the obstruction of bile flow through intra-or extra-hepatic bile ducts. This impairment in bile secretion occurs at somewhere between the liver cells (which produce bile) and the duodenum (the first segment of the small intestine).<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Cholestatic Pruritus Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">As per the Royal College of Obstetricians and Gynaecologists, the United Kingdom, obstetric cholestasis is a multifactorial condition of pregnancy characterized by pruritus in the absence of a skin rash with abnormal liver function tests. In England, this condition affects nearly 1% of pregnancies in multiethnic populations.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A 2015 study titled &ldquo;Drug treatment of pruritus in liver diseases&rdquo; by Hegade et al., suggests that there is considerable variation in the frequency and prevalence of pruritus in different cholestatic conditions. For instance, it is experienced by up to 80% of patients with primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) and by 5&ndash;15% of patients with chronic hepatitis C at any time during the course of their disease. It is less common in patients with extrahepatic cholestatic pruritus, as in one series pruritus occurred in 17%<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Cholestatic Pruritus Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report provides an in-depth analysis of <strong>Cholestatic Pruritus Market Size, Share, Trend, and Epidemiology Forecast<\/strong> till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report will help in developing business strategies by understanding the Cholestatic Pruritus Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report covers the <strong>Cholestatic Pruritus current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in the seven major markets.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the Cholestatic Pruritus market in terms of market drivers &amp; barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Cholestatic Pruritus Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><em><strong>Cholestatic Pruritus Market Size is expected to increase during the forecast period owing to the launch of upcoming therapies.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Cholestatic Pruritus market size and share<\/strong> by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Cholestatic Pruritus market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\"><em><strong>Request for Sample @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Cholestatic Pruritus Therapeutics Market Assessment<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Cholestatic Pruritus Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights about the historical and current Cholestatic Pruritus patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Cholestatic Pruritus Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cholestatic Pruritus market or expected to get launched in the market during the study period. The analysis covers <strong>Cholestatic Pruritus market<\/strong> uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The report also covers the <strong>Cholestatic Pruritus Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>The dynamics of the Cholestatic Pruritus market is anticipated to change in the coming years owing to the improvement in the diagnostic methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><em><strong>Currently, several major pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the QoL of patients with Cholestasis.&nbsp;<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GlaxoSmithKline&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mirum Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Albireo Pharma&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intercept Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cymabay Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Care Therapeutics&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Cholestatic Pruritus Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">GSK2330672<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Maralixibat<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Odevixibat<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Seladelpar<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Korsuva<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Cholestatic Pruritus Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Cholestatic Pruritus Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Cholestatic Pruritus Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Cholestatic Pruritus Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Cholestatic Pruritus Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Cholestatic Pruritus Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Cholestatic Pruritus Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Cholestatic Pruritus Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Cholestatic Pruritus Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Cholestatic Pruritus Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Cholestatic Pruritus Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Cholestatic Pruritus Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Cholestatic Pruritus Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Cholestatic Pruritus Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Cholestatic Pruritus Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Cholestatic Pruritus Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-market<\/a><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metastatic-merkel-cell-carcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><br \/><\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Reports By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/cholestatic-pruritus-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Cholestatic Pruritus Pipeline Insights<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Cholestatic Pruritus Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cholestatic Pruritus market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/global-messenger-rna-market\">mRNA Vaccines and Therapeutics Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &lsquo;Global Messenger RNA (mRNA) based Vaccines and Therapeutics Market Insights, Epidemiology, and Market Forecast 2030&rsquo; report deliver an in-depth understanding of the mRNA-based Vaccines and Therapeutics, along with its historical and forecasted epidemiology and market trends in North America, Europe, Asia, and ROW (rest of the world).<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong><strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=cholestatic-pruritus-market-size-and-share-analysis-clinical-developmental-activities-key-growth-factors-leading-companies-emerging-therapies-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=cholestatic-pruritus-market-size-and-share-analysis-clinical-developmental-activities-key-growth-factors-leading-companies-emerging-therapies-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Cholestatic Pruritus Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cholestatic Pruritus Market Size and Share in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/cholestatic-pruritus-market-size-and-share-analysis-clinical-developmental-activities-key-growth-factors-leading-companies-emerging-therapies-and-epidemiology-forecast_556154.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-556154","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=556154"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/556154\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=556154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=556154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=556154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}